Prasoon Chaturvedi

C4 Therapeutics (United States) — United States

Medicine · Health Sciences

22h-index3.6kcitations106works0.82yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Lung Cancer Treatments and Mutations(40), Radiopharmaceutical Chemistry and Applications(24), Infant Nutrition and Health(23), HER2/EGFR in Cancer Research(14), Breastfeeding Practices and Influences(12)

Publications106 total

Discovery of CFT8634, a Potent, Selective, and Orally Bioavailable Heterobifunctional Degrader of BRD9
Journal of Medicinal Chemistry·2025· 3 cited
CFT1946 Is an Orally Available Brain-Penetrant BRAFV600-Mutant Degrader That Overcomes BRAF Inhibitor Resistance
Cancer Research·2025· 1 cited
CFT8634, a potent, selective and orally bioavailable BiDACTM degrader of BRD9, highlights the potential of C4T’S TORPEDO® platform to develop degraders with excellent drug-like properties against currently undruggable targets
Drug Metabolism and Pharmacokinetics·2025
Determination of steady state brain KP,UU of BIDAC(TM) degraders using chemical knock out animal models
Drug Metabolism and Pharmacokinetics·2025
Discovery of an orally bioavailable, CNS active pan-mutant RET kinase heterobifunctional degrader
RSC Medicinal Chemistry·2025Open Access
CFT7455, a novel IKZF1/3 degrader, demonstrates potent activity in peripheral and CNS models of NHL as a single agent or in combination with clinically approved agents
Hematological Oncology·2023· 5 citedOpen Access
Supplementary Figure 6 from Discovery of a Mutant-Selective Covalent Inhibitor of EGFR that Overcomes T790M-Mediated Resistance in NSCLC
2023Open Access
Supplementary Figure 9 from Discovery of a Mutant-Selective Covalent Inhibitor of EGFR that Overcomes T790M-Mediated Resistance in NSCLC
2023Open Access
Supplementary Tables 1 through 4 and Supplementary Figures 1 through 5 from <i>In Vitro</i> and <i>In Vivo</i> Characterization of Irreversible Mutant-Selective EGFR Inhibitors That Are Wild-Type Sparing
2023Open Access
Supplementary Table 3 from Discovery of a Mutant-Selective Covalent Inhibitor of EGFR that Overcomes T790M-Mediated Resistance in NSCLC
2023Open Access
Supplementary Table 2 from Discovery of a Mutant-Selective Covalent Inhibitor of EGFR that Overcomes T790M-Mediated Resistance in NSCLC
2023Open Access
Supplementary Figure 1 from Discovery of a Mutant-Selective Covalent Inhibitor of EGFR that Overcomes T790M-Mediated Resistance in NSCLC
2023Open Access
Supplementary Figure 5 from Discovery of a Mutant-Selective Covalent Inhibitor of EGFR that Overcomes T790M-Mediated Resistance in NSCLC
2023Open Access
Supplementary Figure 10 from Discovery of a Mutant-Selective Covalent Inhibitor of EGFR that Overcomes T790M-Mediated Resistance in NSCLC
2023Open Access
Supplementary Figure 3 from Discovery of a Mutant-Selective Covalent Inhibitor of EGFR that Overcomes T790M-Mediated Resistance in NSCLC
2023Open Access
Supplementary Figure 6 from Discovery of a Mutant-Selective Covalent Inhibitor of EGFR that Overcomes T790M-Mediated Resistance in NSCLC
2023Open Access
Supplementary Figure 8 from Discovery of a Mutant-Selective Covalent Inhibitor of EGFR that Overcomes T790M-Mediated Resistance in NSCLC
2023Open Access
Supplementary Figure 8 from Discovery of a Mutant-Selective Covalent Inhibitor of EGFR that Overcomes T790M-Mediated Resistance in NSCLC
2023Open Access
Supplementary Figure 2 from Discovery of a Mutant-Selective Covalent Inhibitor of EGFR that Overcomes T790M-Mediated Resistance in NSCLC
2023Open Access
Supplementary Figure 7 from Discovery of a Mutant-Selective Covalent Inhibitor of EGFR that Overcomes T790M-Mediated Resistance in NSCLC
2023Open Access
page 1 of 6Next →

Frequent Co-authors

David S. Newburg(22), Guillermo M. Ruiz‐Palacios(11), Roman V. Agafonov(9), Stewart L. Fisher(9), Michael P. Sheets(8), Mariana Nacht(8), Russell C. Petter(8), William Westlin(8), Scott J. Eron(8), Christopher G. Nasveschuk(8), Roy M. Pollock(8), Juswinder Singh(7), Ardythe L. Morrow(7), Larry K. Pickering(7), Christopher D. Warren(7), Matthew Labenski(6), Thia St Martin(6), Russell Karp(6), Christina S. Henderson(6), Adam Crystal(6)